AAVanced™ Concentration Reagent (100 ml aliquot)

AAVancedTM Concentration Reagent (100 ml aliquot). Cat# AAV100A. Supplier: SBI System Biosciences

Overview

Streamline gene therapy development and other AAV-based applications

With a simple one-step protocol to concentrate AAV particles from media, you can streamline your gene therapy development and other projects that rely on AAV transduction.

• Easy to use, single reagent
• Isolate rAAV directly from media
• No cell lysates or centrifugation
• Save time and cost-effective
• Compatible with all serotypes

Unlike conventional AAV isolation methods which are labor-intensive, multi-step, and require cell lysis, CsCl₂ density gradient ultracentrifugation, and chromatography, SBI’s AAVanced™ Concentration Reagent isolates rAAV particles from media in a single easy step. Simply add AAVanced Concentration Reagent to AAV particle-containing media, incubate overnight at 4°C, and then spin at 1,500g for thirty minutes. Wash the pellet once, spinning again for only three minutes, and then resuspend and aliquot the concentrated virus. Titers of the isolated AAV particles are similar to titers of AAV particles isolated with traditional methods (Figure 1).

Figure 1.AAVanced Concentration Reagent delivers AAV particle preps with similar titers as AAV particles prepared using conventional methods.  rAAV was packaged with a PGK-GFP expression shuttle vector. The rAAV particles were isolated from packaging cell media either by the conventional method—cell lysis freeze-thaw with density gradient ultracentrifugation—or with the AAVanced Concentration Reagent. Equal amounts of rAAV were then added to HEK293 cells to test for infectivity based on GFP expression. Representative images of GFP expressing cells 10-days after infection show similar levels of infectivity.

How It Works

Delivering a streamlined workflow for easier gene therapy and other AAV projects

Supporting Data

Demonstrably high titer with rAAV isolated using AAVanced Concentration Reagent

Figure 2. rAAV particles isolated using AAVanced Concentration Reagent are present at high copy numbers in 293T cells. A small volume of the rAAV virus isolated using AAVanced Concentration Reagent was used to infect 3×10⁵ 293T cells in a 24-well culture dish. The cells were imaged after 72-hours and rAAV copy numbers quantitated by qPCR. The copy numbers measured for the PGK-GFP rAAV virus were quite high at 2×10¹³ copies/mL.

Figure 3. AAVanced Concentration Reagent works with multiple serotypes in vitro. The same rAAV shuttle vector with a PGK promoter driving GFP expression was packaged in parallel into three different AAV serotypes: AAV-2, AAV-DJ and AAV-5. After 48-hours, media was collected and rAAV particles isolated using the AAVanced Concentration Reagent. Each rAAV particle pellet was resuspended in 100 mL of sterile PBS, and then 1 mL of the rAAV suspensions were added to three different cell lines (HEK293T, HT1080 and CHO) to validate transduction efficiencies.

The infected cells were imaged for GFP expression 6-days after addition of the isolated rAAV particles. All serotypes of rAAV were able to infect the three different cell types tested, demonstrating the broad compatibility of AAVanced Concentration Reagent.